- Stocks
- Healthcare
- NASDAQ: CTSO

Price (delayed)

$3.27

Market cap

$142.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.75

Enterprise value

$137.09M

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the

CTSO's net income is down by 34% year-on-year but it is up by 21% since the previous quarter

CTSO's EPS is down by 32% YoY but it is up by 22% from the previous quarter

The equity has declined by 43% year-on-year and by 10% since the previous quarter

The debt has increased by 39% since the previous quarter and by 37% year-on-year

What are the main financial stats of CTSO

Market
Valuations
Earnings

Shares outstanding

43.66M

Market cap

$142.78M

Enterprise value

$137.09M

Price to earnings (P/E)

N/A

Price to book (P/B)

4.03

Price to sales (P/S)

4.11

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

3.95

Revenue

$34.69M

EBIT

-$34.04M

EBITDA

-$32.91M

Free cash flow

-$34.32M

Per share
Balance sheet
Liquidity

EPS

-$0.75

Free cash flow per share

-$0.79

Book value per share

$0.81

Revenue per share

$0.8

TBVPS

$1.45

Total assets

$63.23M

Total liabilities

$27.86M

Debt

$18.14M

Equity

$35.37M

Working capital

$24.05M

Debt to equity

0.51

Current ratio

3.48

Quick ratio

3.04

Net debt/EBITDA

0.17

Margins
Efficiency
Dividend

EBITDA margin

-94.9%

Gross margin

59.8%

Net margin

-94.6%

Operating margin

-90.9%

Return on assets

-46.9%

Return on equity

-73.9%

Return on invested capital

-81.2%

Return on capital employed

-63.6%

Return on sales

-98.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Cytosorbents stock price performed over time

Intraday

-3.82%

1 week

1.55%

1 month

-0.3%

1 year

7.92%

YTD

110.97%

QTD

110.97%

How have Cytosorbents's revenue and profit performed over time

Revenue

$34.69M

Gross profit

$20.73M

Operating income

-$31.52M

Net income

-$32.81M

Gross margin

59.8%

Net margin

-94.6%

Cytosorbents's operating margin has shrunk by 72% YoY but it has increased by 6% QoQ

The net margin has dropped by 66% year-on-year but it has increased by 17% since the previous quarter

CTSO's operating income is down by 39% year-on-year but it is up by 9% since the previous quarter

The gross profit has declined by 35% year-on-year and by 8% since the previous quarter

What is Cytosorbents's growth rate over time

What is Cytosorbents stock price valuation

P/E

N/A

P/B

4.03

P/S

4.11

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

3.95

CTSO's EPS is down by 32% YoY but it is up by 22% from the previous quarter

CTSO's P/B is 102% higher than its last 4 quarters average of 2.0 but 64% lower than its 5-year quarterly average of 11.1

The equity has declined by 43% year-on-year and by 10% since the previous quarter

The stock's price to sales (P/S) is 71% more than its last 4 quarters average of 2.4 but 50% less than its 5-year quarterly average of 8.3

Cytosorbents's revenue has decreased by 20% YoY and by 3.9% QoQ

How efficient is Cytosorbents business performance

The ROE has plunged by 114% YoY but it has grown by 9% from the previous quarter

The ROA has shrunk by 77% YoY but it has increased by 13% QoQ

CTSO's ROS has plunged by 67% YoY but it is up by 16% from the previous quarter

The ROIC has grown by 25% from the previous quarter and by 7% YoY

What is CTSO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CTSO.

How did Cytosorbents financials performed over time

The company's total assets is 127% higher than its total liabilities

The company's total assets fell by 29% YoY

The quick ratio is down by 29% YoY but it is up by 5% QoQ

The debt is 49% smaller than the equity

The debt to equity has soared by 143% year-on-year and by 55% since the previous quarter

The equity has declined by 43% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.